149 related articles for article (PubMed ID: 30070014)
1. Resource utilization and toxicities after single versus tandem autologous stem cell rescue in high-risk neuroblastoma using a national administrative database.
Desai AV; Li Y; Getz K; Seif AE; Fisher B; Huang V; Aplenc R; Bagatell R
Pediatr Blood Cancer; 2018 Dec; 65(12):e27372. PubMed ID: 30070014
[TBL] [Abstract][Full Text] [Related]
2. Resource Utilization and Toxicities After Carboplatin/Etoposide/Melphalan and Busulfan/Melphalan for Autologous Stem Cell Rescue in High-Risk Neuroblastoma Using a National Administrative Database.
Desai AV; Seif AE; Li Y; Getz K; Fisher BT; Huang V; Mante A; Aplenc R; Bagatell R
Pediatr Blood Cancer; 2016 May; 63(5):901-7. PubMed ID: 26797923
[TBL] [Abstract][Full Text] [Related]
3. Toxicities of busulfan/melphalan versus carboplatin/etoposide/melphalan for high-dose chemotherapy with stem cell rescue for high-risk neuroblastoma.
Desai AV; Heneghan MB; Li Y; Bunin NJ; Grupp SA; Bagatell R; Seif AE
Bone Marrow Transplant; 2016 Sep; 51(9):1204-10. PubMed ID: 27159174
[TBL] [Abstract][Full Text] [Related]
4. Tandem high-dose chemotherapy with autologous stem cell rescue for stage M high-risk neuroblastoma: Experience using melphalan/etoposide/carboplatin and busulfan/melphalan regimens.
Kato S; Kubota Y; Watanabe K; Hogetsu K; Arakawa Y; Koh K; Takita J; Hiwatari M
Pediatr Transplant; 2020 Nov; 24(7):e13772. PubMed ID: 32543778
[TBL] [Abstract][Full Text] [Related]
5. Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial.
Ladenstein R; Pötschger U; Pearson ADJ; Brock P; Luksch R; Castel V; Yaniv I; Papadakis V; Laureys G; Malis J; Balwierz W; Ruud E; Kogner P; Schroeder H; de Lacerda AF; Beck-Popovic M; Bician P; Garami M; Trahair T; Canete A; Ambros PF; Holmes K; Gaze M; Schreier G; Garaventa A; Vassal G; Michon J; Valteau-Couanet D;
Lancet Oncol; 2017 Apr; 18(4):500-514. PubMed ID: 28259608
[TBL] [Abstract][Full Text] [Related]
6. Tandem high-dose chemotherapy with thiotepa and busulfan-melphalan and autologous stem cell transplantation in very high-risk neuroblastoma patients.
Pasqualini C; Dufour C; Goma G; Raquin MA; Lapierre V; Valteau-Couanet D
Bone Marrow Transplant; 2016 Feb; 51(2):227-31. PubMed ID: 26524264
[TBL] [Abstract][Full Text] [Related]
7. High-dose Carboplatin/Etoposide/Melphalan increases risk of thrombotic microangiopathy and organ injury after autologous stem cell transplantation in patients with neuroblastoma.
Jodele S; Dandoy CE; Myers K; Wallace G; Lane A; Teusink-Cross A; Weiss B; Davies SM
Bone Marrow Transplant; 2018 Oct; 53(10):1311-1318. PubMed ID: 29674658
[TBL] [Abstract][Full Text] [Related]
8. Changes in glomerular filtration rate and clinical course after sequential doses of carboplatin in children with embryonal brain tumors undergoing autologous stem cell transplantation.
Elborai Y; Almutereen M; Maher OM; Hafez H; Lee MA; Lehmann L
J Egypt Natl Canc Inst; 2020 Feb; 32(1):9. PubMed ID: 32372349
[TBL] [Abstract][Full Text] [Related]
9. Comparison of toxicity following different conditioning regimens (busulfan/melphalan and carboplatin/etoposide/melphalan) for advanced stage neuroblastoma: Experience of two transplant centers.
Elborai Y; Hafez H; Moussa EA; Hammad M; Hussein H; Lehmann L; Elhaddad A
Pediatr Transplant; 2016 Mar; 20(2):284-9. PubMed ID: 26614402
[TBL] [Abstract][Full Text] [Related]
10. 131I-MIBG followed by consolidation with busulfan, melphalan and autologous stem cell transplantation for refractory neuroblastoma.
French S; DuBois SG; Horn B; Granger M; Hawkins R; Pass A; Plummer E; Matthay K
Pediatr Blood Cancer; 2013 May; 60(5):879-84. PubMed ID: 23024113
[TBL] [Abstract][Full Text] [Related]
11. Tandem high-dose chemotherapy with topotecan-thiotepa-carboplatin and melphalan-etoposide-carboplatin regimens for pediatric high-risk brain tumors.
Choi JY; Kang HJ; Hong KT; Hong CR; Lee YJ; Park JD; Phi JH; Kim SK; Wang KC; Kim IH; Park SH; Choi YH; Cheon JE; Park KD; Shin HY
Int J Clin Oncol; 2019 Dec; 24(12):1515-1525. PubMed ID: 31352632
[TBL] [Abstract][Full Text] [Related]
12. Incorporation of high-dose
Lee JW; Lee S; Cho HW; Ma Y; Yoo KH; Sung KW; Koo HH; Cho EJ; Lee SK; Lim DH
J Hematol Oncol; 2017 May; 10(1):108. PubMed ID: 28511709
[TBL] [Abstract][Full Text] [Related]
13. Outcome for children <4 years of age with malignant central nervous system tumors treated with high-dose chemotherapy and autologous stem cell rescue.
Thorarinsdottir HK; Rood B; Kamani N; Lafond D; Perez-Albuerne E; Loechelt B; Packer RJ; MacDonald TJ
Pediatr Blood Cancer; 2007 Mar; 48(3):278-84. PubMed ID: 16456857
[TBL] [Abstract][Full Text] [Related]
14. Acute Complications After High-Dose Chemotherapy and Stem-Cell Rescue in Pediatric Patients With High-Risk Neuroblastoma Treated in Countries With Different Resources.
Elzembely MM; Park JR; Riad KF; Sayed HA; Pinto N; Carpenter PA; Baker KS; El-Haddad A
J Glob Oncol; 2018 Sep; 4():1-12. PubMed ID: 30241255
[TBL] [Abstract][Full Text] [Related]
15. Successful treatment of metastatic retinoblastoma with high-dose chemotherapy and autologous stem cell rescue in South America.
Palma J; Sasso DF; Dufort G; Koop K; Sampor C; Diez B; Richard L; Castillo L; Chantada GL
Bone Marrow Transplant; 2012 Apr; 47(4):522-7. PubMed ID: 21602901
[TBL] [Abstract][Full Text] [Related]
16. Feasibility of Busulfan Melphalan and Stem Cell Rescue After 131I-MIBG and Topotecan Therapy for Refractory or Relapsed Metastatic Neuroblastoma: The French Experience.
Ferry I; Kolesnikov-Gauthier H; Oudoux A; Cougnenc O; Schleiermacher G; Michon J; Bogart E; Chastagner P; Proust S; Valteau-Couanet D; Defachelles AS
J Pediatr Hematol Oncol; 2018 Aug; 40(6):426-432. PubMed ID: 29642099
[TBL] [Abstract][Full Text] [Related]
17. High-dose chemotherapy with autologous stem cell rescue in children with nephroblastoma.
Kremens B; Gruhn B; Klingebiel T; Hasan C; Laws HJ; Koscielniak E; Hero B; Selle B; Niemeyer C; Finckenstein FG; Schulz A; Wawer A; Zintl F; Graf N
Bone Marrow Transplant; 2002 Dec; 30(12):893-8. PubMed ID: 12476282
[TBL] [Abstract][Full Text] [Related]
18. High-dose carboplatin, thiotepa, and etoposide with autologous stem-cell rescue for patients with recurrent medulloblastoma. Children's Cancer Group.
Dunkel IJ; Boyett JM; Yates A; Rosenblum M; Garvin JH; Bostrom BC; Goldman S; Sender LS; Gardner SL; Li H; Allen JC; Finlay JL
J Clin Oncol; 1998 Jan; 16(1):222-8. PubMed ID: 9440746
[TBL] [Abstract][Full Text] [Related]
19. High-dose chemotherapy with autologous stem-cell rescue in children and adults with newly diagnosed pineoblastomas.
Gururangan S; McLaughlin C; Quinn J; Rich J; Reardon D; Halperin EC; Herndon J; Fuchs H; George T; Provenzale J; Watral M; McLendon RE; Friedman A; Friedman HS; Kurtzberg J; Vredenbergh J; Martin PL
J Clin Oncol; 2003 Jun; 21(11):2187-91. PubMed ID: 12775745
[TBL] [Abstract][Full Text] [Related]
20. Feasibility and Safety of Treosulfan, Melphalan, and Thiotepa-Based Megachemotherapy with Autologous or Allogeneic Stem Cell Transplantation in Heavily Pretreated Children with Relapsed or Refractory Neuroblastoma.
Wawrzyniak-Dzierżek E; Gajek K; Rybka B; Ryczan-Krawczyk R; Węcławek-Tompol J; Raciborska A; Mielcarek-Siedziuk M; Frączkiewicz J; Salamonowicz M; Kałwak K; Rosa M; Ślęzak A; Ussowicz M
Biol Blood Marrow Transplant; 2019 Sep; 25(9):1792-1797. PubMed ID: 31085306
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]